Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
– Closed registered direct offering for aggregate gross proceeds of US$175 million (the "Registered Direct Offering") led by a syndicate of prominent biopharmaceutical institutional investors – – On track to report topline data from Phase 2 study evaluating C
(Financial Post, 2025-11-13T12:27:05Z)